Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 3/20 | 0.34 |
| ▸ | CDK8 | P49336 | 3/20 | 0.34 |
| ▸ | RAF1 | P04049 | 3/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | ERG | P11308 | 3/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30257455 | 0.89 | AKT1 (0.43) | AKT1CCNCCDK8RAF1BRAF | |
| SCHEMBL25058669 | 0.89 | AKT1 (0.43) | AKT1CCNCCDK8RAF1BRAF | |
| SCHEMBL25568289 | 0.87 | AKT1 (0.37) | AKT1CCNCCDK8RAF1BRAF | |
| SCHEMBL30256596 | 0.81 | LMNA (0.42) | AKT1ALDH1A1 | |
| SCHEMBL23949247 | 0.81 | LMNA (0.42) | AKT1ALDH1A1 | |
| SCHEMBL23949225 | 0.79 | AKT1 (0.44) | AKT1CCNCCDK8RAF1BRAF | |
| SCHEMBL25555360 | 0.76 | PIK3CA (0.42) | AKT1HPGDALDH1A1 | |
| SCHEMBL25057826 | 0.76 | LMNA (0.43) | AKT1EGLN1ALDH1A1 | |
| SCHEMBL30353082 | 0.76 | LMNA (0.43) | AKT1EGLN1ALDH1A1 | |
| SCHEMBL30353124 | 0.76 | ALDH1A1 (0.41) | AKT1HPGDERGGPBAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | AKT1 1144/4885CCNC 2179/4885CDK8 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.